in London, UK. The primary goals of the conference were as follows: to understand current perspectives on physiology and pathology of erectile dysfunction (ED); to discuss the value of existing tools to diagnose and evaluate ED; to discuss state-of-theart clinical data for commercial and developmentstage therapies; and to assess recent advances in the treatment of ED.
The Second International Conference on Management of Erectile Dysfunction: New Perspectives on Treatment, co-chaired by Ajay Nehra, MD, and John Pryor, MD, was held 28 -29 June 2001, in London, UK. The primary goals of the conference were as follows: to understand current perspectives on physiology and pathology of erectile dysfunction (ED); to discuss the value of existing tools to diagnose and evaluate ED; to discuss state-of-theart clinical data for commercial and developmentstage therapies; and to assess recent advances in the treatment of ED.
The conference was designed for an invited expert clinical faculty who wished to expand their knowledge and contribute new information and perspectives regarding new advances and opportunities in the management of ED. The attendees were internationally prominent experts in the fields of urology, epidemiology, clinical pharmacology, and marital and sexual health, and included representatives from Sweden, Spain, Germany, Belgium, France, The Netherlands, Norway, Greece, Italy, the UK, and the USA.
The informal format of the conference, which combined brief scientific reports with extended periods of open discussion, offered participants the opportunity to exchange information and develop hypotheses with immediate input and constructive critiques from their multidisciplinary and multinational colleagues. The conference participants presented, discussed and debated such critical issues as erectile physiology and pathophysiology, prevalence and diagnosis of ED, clinical challenges in drug development and treatment of sexual dysfunction. However, the intellectual and scientific range of the conference extended well beyond these topics to cover such broader issues as epidemiology, risk factors and preventive measures, men's health, reasons for discontinuation of treatment, diagnosis, design and standardization of trials, individual drugs, combination therapy and future therapies.
An Executive Committee met in a special session to summarize the debate and the conclusions of the 2-day meeting. The deliberations of the Executive Committee served two purposes: to formulate what was learned or established during the conference and to state unresolved issues and unanswered questions for presentation to the specialties involved in treatment of ED, questions that will be taken up at the next annual meeting. 
The summary
Based on data reviewed during the conference, the Executive Committee believes that there are currently therapies available to treat nearly all patients with ED. The majority of men with ED can expect that treatment can restore their erections. However, as is true with all successful therapies, there is a high discontinuation rate in patients undergoing treatment for ED. Because of this discontinuation phenomenon, men and their partners need to be educated and=or counseled in how to achieve satisfactory coital experiences. The treatment of ED goes beyond the penis and must encompass the relationship and the partner.
Epidemiology
In 1995, there was an estimated projection of 152 million men worldwide who experienced ED; for 2025, this projection is 322 million men with ED. The cause of age-related dysfunction is poorly understood and is likely to be multifactorial in origin. The incidence of ED increases with age and the presence of concomitant conditions. Although the Executive Committee believes that the current prevalence data regarding ED are strong, they see a need for strengthening the incidence data. Currently, there is only one study that examines the incidence of ED, the follow-up of the Massachusetts Male Aging Study (MMAS). In the MMAS, men between the ages of 40 and 70 y were asked to categorize their erectile function as potent or totally, moderately, or minimally impotent. In all, 52% of the sample reported some amount of ED. Yet in attempting to compare the MMAS with other studies, particularly studies performed in Europe, we often encounter significantly different prevalence incidence. For example, a peer reviewed study from Italy cites that 13% of the male population has ED. 1 The different methods used to perform these studies cause wide discrepancies in the reporting of prevalence incidence data. Another factor that affects the accuracy of incidence reporting is the so-called bothersomeness factor. For example, according to the MMAS, 52% of men have ED, but it is not known how many of these men need or want treatment.
The Executive Committee believes that attempting to determine whether ED stems from a psychogenic or an organic origin is problematic in determining the true prevalence incidence of ED because it is a diagnosis of exclusion. The committee recommends using mild, moderate and severe classifications of ED and reserving organic, psychogenic, and mixed classifications for diagnostic considerations. It is also important to consider both psychological and biological risk factors, as described in both the US 2 and UK 3 guidelines for treating ED, in determining the origin of ED.
Physiology and pathophysiology
Most basic and clinical studies of ED have shown the condition to be caused by a variety of psychological and=or organic factors. Many of these factors have a direct effect on the central and peripheral mechanisms of action of erectile function. During the conference, both the central and peripheral mechanisms of action were discussed, and particular attention was drawn to the five synergistic systems of penile erection: cyclic guanosine monophosphate, cyclic adenosine monophosphate, calcium channels, protein kinases and potassium channels. Extensive data on the peripheral mechanisms of the penis are now available. Peripherally, the signals from the central nervous system influence the balance between the contractant and relaxant factors that control the degree of contraction of the smooth muscle of the corpora cavernosa and determine the functional state of the penis. However, the different steps involved in neurotransmission, impulse, propagation and intracellular transduction of neural signals in penile smooth muscles need further investigation. Research on the mechanisms of central-reacting agents is less extensive. Studies should be performed in this area, particularly with regard to the central effects of apomorphine. In addition, future studies need to determine if we can pharmacologically influence sexual drive or if any of the currently available drugs have effects in this direction. Additional studies should be performed to discover whether a-melanocyte-stimulating hormone and melanocortin receptor stimulation or serotonin 5HT 2c receptor stimulation are good therapeutic alternatives in the treatment of ED.
Risk factors and preventive measures
The prevalence and incidence of ED increase with age and the presence of concomitant conditions, such as diabetes mellitus, heart disease, hypertension, depression, pelvic surgery, negative mood, lack of self-esteem, problems with relationships, or inadequate sexual experience. Vascular disease is thought to be the most common cause of organic ED, and it may be an early symptom of cardiac morbidity and mortality. A correlation has also been found between the severity of ischemic coronary disease and ED. In addition, there is a correspondingly above average prevalence of ED among men treated with cardiovascular drugs and antidepressants. Moreover, lower urinary tract symptoms and current or previous medical treatment of benign prostatic hypertrophy also correlate with the occurrence of sexual dysfunction.
Counseling, adjustment of lifestyle, and modification of risk factors, such as medication, overweight, smoking, excessive alcohol consumption, and lack of exercise, are the primary steps in a holistic approach toward the treatment of ED. It is especially important for men with ED to remain as physically and sexually active as possible for as long as possible.
There is a large population of 'silent sufferers', men with ED who are not seeking treatment. Current projections, which are based on the presumption that in 2025 about 322 million men worldwide will experience ED, estimate that only 100 million men of that 322 million will opt for treatment. Two reasons for this are the patients' discomfort in discussing the problem and their confusion about where to seek treatment. According to a recent US poll, 71% of people thought that their physicians would not take them seriously and 68% believed that their physicians would be embarrassed by the discussion. 4 The Executive Committee recommends education of both practitioners and the public regarding the need to seek medical attention for the treatment of ED.
Overview consensus statement
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Diagnosis
Because of the variety of treatments currently available to treat ED, a detailed diagnostic workup now plays an even more pivotal role in diagnosing ED. During the workup, physicians should measure testosterone and cholesterol levels. It is also essential for physicians to exclude diabetes and other hormonal disorders, such as hyperprolactinemia. In addition, serious consideration should be given to performing lipid profiles in men older than 50 y. The remainder of the examination should be used as a screening opportunity. In some cases, ED may be caused by another disease or medical event, such as a myocardial infarction. It is sensible to bear in mind the cardiac status of the patient before recommending resumption of sexual activity. If possible, the patient's partner should also be assessed for health issues that may influence the outcome of therapy, for example, vaginal atrophy. In the future, it may prove important to perform other selective tests to assess the appropriateness of certain forms of therapy.
Therapy
Today there are many effective therapies for the treatment of ED. First-line therapies include oral pharmacotherapy and psychosexual therapy. Second-line therapies include intraurethral and intracavernosal administration of vasoactive drugs, vacuum devices and penile protheses. Vacuum devices can be used as first-line therapy in couples who do not want pharmacological intervention and are not appropriate for counseling. Although there used to be a high incidence of mechanical failure, there continue to be improvements in the mechanical reliability of penile prostheses and new modifications have reduced infection rates. This makes for a highly effective treatment in carefully selected patients. Topical administration of vasoactive substances has the potential to become a first-line therapy for ED because of its ease of use and the positive patient perception of this approach. The current problem in the development of this approach is the search for an effective system to facilitate skin and tunica permeation. Currently, phase 2 and 3 studies are ongoing in Europe and the US to identify the best drug formulation and verify its safety and efficacy profile. In China, a topical alprostadil formulation has just been approved. Although it is now possible for almost all men with ED to regain their erections, getting those men to use their erections regularly is more complicated. Discontinuation rates for any of the available medical treatments for ED, including sildenafil, have been found to range from 50 to 60%. Thus, a disproportionately high number of individuals do not continue using medical interventions compared with those for whom treatment is efficacious. This high treatment discontinuation rate may be attributable to psychological factors, for example, the couple's expectations and feelings regarding the treatment and their sexual relationship. To effectively treat ED, clinicians must address not only the medical factors but also the psychological factors involved in ED. To date, however, no controlled studies of ED therapy have examined whether such an integrated method would be more successful than either a medical or psychological treatment alone. Designing and testing the elements of a combined treatment with matched treatment and control groups are recommended.
Design and standardization of trials
Because of the recent increase in the number of new drugs for the treatment of ED, standardized, highquality protocols for evaluation of the therapeutic effect of these treatments are necessary. Outcome analyses have to rely on prospective, placebocontrolled trials within predefined populations, where the results are based on objective physiological assessments, self-administered assessments, partner assessments, quality of life and treatment satisfaction. Information from toxicological analyses and phase 1 studies forms a solid basis for performing phase 2 crossover studies and phase 3 and phase 4 studies. It is dangerous to directly compare different phase 2 and phase 3 trials because of the differences in patient populations and end points. Increasingly, end points are becoming standardized, which should aid in the comparability of different trials. Currently, the best efficacy end points are subtracting the placebo rate from the active rate and the number of sexual intercourses with vaginal penetration to completion. Such data may be available through patient sexual event diaries rather than questionnaires that evaluate monthly changes (for example, the International Index of Erectile Function score).
Most trials exhibit a conspicuously high placebo effect, which is of concern in translating the trial outcome. More long-term (1-or 2-y), methodologically sound trials may moderate this placebo effect and are needed to measure the continuation of treatment dropout. In addition, the correlation among the pharmacological, physiological, human, and animal data needs to be assessed. The Executive Committee awaits with interest studies that examine the relationship between potency and specificity in the clinical setting.
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Pharmacology
During the past 3 y sildenafil (Viagra), the only oral phosphodiesterase-5 (PDE-5) inhibitor currently on the market, has demonstrated good efficacy and established safety. However, high discontinuation rates exist for oral ED treatment. The Executive Committee believes that this discontinuation is due to inadequate education, counseling, and=or knowledge of the patients and their sexual partner by their physicians. The Executive Committee recommends that the physician encourages open and active communication with the patient both at the time of sildenafil administration and also during follow-up. Patients who are closely monitored can be advised regarding alternative therapies and the reasons for treatment failure or opportunities to maintain success can be explored.
The early data in clinical trials on apomorphine are promising. The drug, which was approved by the EMEA in 2001, has shown a statistically significant improvement in ED patients compared with placebo and has established efficacy and safety. In addition, no modification of sexual desire has been noted with use of apomorphine and there are no contraindications when it is taken with other drugs. However, mechanisms involved in the rare event of syncope are not well understood. The Executive Committee recommends further research on the drug's mechanisms of action.
Tadalafil is a potent and selective PDE-5 inhibitor currently under investigation as a treatment for ED. The drug is orally administered and rapidly absorbed. Studies performed in Europe, the US, and Canada reported improved erections in 51 -90% of patients taking tadalafil according to the Global Assessment Question. These data indicate that tadalafil has the potential to become a useful new option for treating ED.
Vardenafil is a potent and selective PDE-5 inhibitor that is under clinical investigation as an oral therapy for ED. The efficacy and safety of vardenafil in short-term studies have been demonstrated. Its efficacy in the initial phase 3 studies in diabetic men with relatively severe ED was surprisingly strong. The effectiveness of the drug in the general population of men with ED and how well it performs compared with other treatment modalities have not yet been reported.
Combination therapies
Because ED has a variety of causes and associated complications, a combination of therapies is often necessary for effective treatment. The obvious aim of combination therapy is to increase efficacy and=or decrease adverse effects. Combinations of apomorphine and sildenafil and apomorphine and a 1 -adrenoceptor antagonists, for example, may have a therapeutic potential in patients not responding to single-drug treatment. A combination of nitric oxide donation and a 1 -or a 2 -adrenoceptor antagonism is currently being evaluated. In addition, a combination of sildenafil and the Medicated Urethral System for Erection (MUSE) may also prove effective in patients who desire noninvasive therapy but in whom singledrug treatments fail. Another combination that may prove effective is oral sildenafil and intracavernous alprostadil. No data, however, exist comparing monotherapies with combination therapies, particularly in terms of safety. Such information is critical before adaptation in clinical practice, since the synergistic effects of the combined drugs may have significant side effects, especially cardiovascular effects.
The drugs most frequently used in combination therapy are prostaglandin E 1 , papaverine, phentolamine and atropine. In selected patients, these combinations can reduce cost and increase efficacy. In fact, multidrug combinations achieve the highest rate of responders with the lowest rate of complications. The main drawback of multidrug therapy is that none of these pharmacologic combinations have been approved by the national health care authorities (the only exception being the papaverine -phentolamine combination in some European countries). The Executive Committee recommends the development of protocols for designing clinical trials to study combination drug therapy.
Areas of future research
The Executive Committee identified several areas for future research: (1) improvement of current therapeutic principles; (2) combinations of existing therapeutic principles; (3) new targets within the central nervous system; (4) new peripheral targets; (5) gene therapy; and (6) prevention strategies.
Consensus clinical summary
In considering the clinical data to date, the Executive Committee reached the following conclusions: Education and counseling of both patients and clinicians are the cornerstones of ED treatment. Both medical and psychological factors must be taken into account when treating ED. The man's sexual partner needs to be a part of ED treatment. Carefully designed controlled clinical trials on oral and local combination therapy and pharmacological and psychological combination therapy need to be performed to optimize treatment.
Further research on the mechanisms of centralreacting agents in the treatment of ED needs to be performed. We need to work toward preventative therapy for ED.
Future directions
Future conferences will continue to address the issues raised in this overview summary and will give more prominence to treatment implications for specific patient populations and the prevention of ED. It is anticipated that an annual meeting of those involved in basic and clinical research and patient care will continue to improve our understanding of ED and further define the opportunities to enhance disease management. 
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